Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Ruffell
Lisa M Coussens

Immunity

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Immunity|April 23, 2013
Some DCs are "B"etterBrian Ruffell, Lisa M Coussens
Immunity|October 12, 2022
Cytokines drive prostate cancer lineage plasticityJie Li, Brian Ruffell
Immunity|January 19, 2018
moDCs, Less ProblemsAlycia Gardner, Brian Ruffell
Immunity|April 3, 2026
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironmentVivien I Maltez, Charu Arora, Kyle P Gribbin, et al.
Immunity|May 12, 2021
The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptakeÁlvaro de Mingo Pulido, Kay Hänggi, Daiana P Celias, et al.
Immunity|April 16, 2020
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING SignalingEslam Mohamed, Rosa A Sierra, Jimena Trillo-Tinoco, et al.
Immunity|July 1, 2018
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to ImmunotherapyJinyang Li, Katelyn T Byrne, Fangxue Yan, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Immunity|April 23, 2013
Some DCs are "B"etterBrian Ruffell, Lisa M Coussens
Immunity|October 12, 2022
Cytokines drive prostate cancer lineage plasticityJie Li, Brian Ruffell
Immunity|January 19, 2018
moDCs, Less ProblemsAlycia Gardner, Brian Ruffell
Immunity|April 3, 2026
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironmentVivien I Maltez, Charu Arora, Kyle P Gribbin, et al.
Immunity|May 12, 2021
The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptakeÁlvaro de Mingo Pulido, Kay Hänggi, Daiana P Celias, et al.
Immunity|April 16, 2020
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING SignalingEslam Mohamed, Rosa A Sierra, Jimena Trillo-Tinoco, et al.
Immunity|July 1, 2018
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to ImmunotherapyJinyang Li, Katelyn T Byrne, Fangxue Yan, et al.
Pageof 1